|
|
Blood, 1 April 2005, Vol. 105, No. 7, pp. 2862-2868.
Prepublished online as a Blood First Edition Paper on December 9, 2004; DOI 10.1182/blood-2004-06-2410.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
M. E. Christine Lutsiak,
Roshanak T. Semnani,
Roberto De Pascalis,
Syed V. S. Kashmiri,
Jeffrey Schlom, and
Helen Sabzevari
From the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health; and Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Regulatory T cells (TREGs) control the key aspects of tolerance and play a role in the lack of antitumor immune responses. Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Although a previous study demonstrated that CY reduces the number of TREGs, the mechanism involved in this process has yet to be defined. In this report, it is established that low-dose CY not only decreases cell number but leads to decreased functionality of TREGs. CY treatment enhances apoptosis and decreases homeostatic proliferation of these cells. Expression of GITR and FoxP3, which are involved in the suppressive activity of TREGs, is down-regulated after CY administration, though the level of expression varies depending on the time studied. This is the first report demonstrating that CY, in addition to decreasing cell number, inhibits the suppressive capability of TREGs. The relevance of the loss of suppressor functionality and the changes in gene expression are further discussed.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. T. Garnett, J. Schlom, and J. W. Hodge
Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement
Clin. Cancer Res.,
June 1, 2008;
14(11):
3536 - 3544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Gulley, P. M. Arlen, K.-Y. Tsang, J. Yokokawa, C. Palena, D. J. Poole, C. Remondo, V. Cereda, J. L. Jones, M. P. Pazdur, et al.
Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
Clin. Cancer Res.,
May 15, 2008;
14(10):
3060 - 3069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schlom, J. L. Gulley, and P. M. Arlen
Paradigm Shifts in Cancer Vaccine Therapy
Experimental Biology and Medicine,
May 1, 2008;
233(5):
522 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. C. Lutsiak, Y. Tagaya, A. J. Adams, J. Schlom, and H. Sabzevari
Tumor-Induced Impairment of TCR Signaling Results in Compromised Functionality of Tumor-Infiltrating Regulatory T Cells
J. Immunol.,
May 1, 2008;
180(9):
5871 - 5881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eto, Y. Kamiryo, A. Takeuchi, M. Harano, K. Tatsugami, M. Harada, K. Kiyoshima, M. Hamaguchi, T. Teshima, M. Tsuneyoshi, et al.
Posttransplant Administration of Cyclophosphamide and Donor Lymphocyte Infusion Induces Potent Antitumor Immunity to Solid Tumor
Clin. Cancer Res.,
May 1, 2008;
14(9):
2833 - 2840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Castano, P. Mroz, M. X. Wu, and M. R. Hamblin
Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model
PNAS,
April 8, 2008;
105(14):
5495 - 5500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Terme, N. Chaput, B. Combadiere, A. Ma, T. Ohteki, and L. Zitvogel
Regulatory T Cells Control Dendritic Cell/NK Cell Cross-Talk in Lymph Nodes at the Steady State by Inhibiting CD4+ Self-Reactive T Cells
J. Immunol.,
April 1, 2008;
180(7):
4679 - 4686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Nishikawa, T. Tsuji, E. Jager, G. Briones, G. Ritter, L. J. Old, J. E. Galan, H. Shiku, and S. Gnjatic
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector
Blood,
February 1, 2008;
111(3):
1404 - 1412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Degl'Innocenti, M. Grioni, G. Capuano, E. Jachetti, M. Freschi, M. T.S. Bertilaccio, R. Hess-Michelini, C. Doglioni, and M. Bellone
Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells
Cancer Res.,
January 1, 2008;
68(1):
292 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al.
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
Clin. Cancer Res.,
January 1, 2008;
14(1):
259 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schlom, P. M. Arlen, and J. L. Gulley
Immunotherapies with Other Therapeutic Modalities: New Paradigms for Clinical Trial Design
ASCO Educational Book,
January 1, 2008;
2008(1):
101 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Litzinger, R. Fernando, T. J. Curiel, D. W. Grosenbach, J. Schlom, and C. Palena
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
Blood,
November 1, 2007;
110(9):
3192 - 3201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Berraondo, C. Nouze, X. Preville, D. Ladant, and C. Leclerc
Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System
Cancer Res.,
September 15, 2007;
67(18):
8847 - 8855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Obeid, T. Panaretakis, A. Tesniere, N. Joza, R. Tufi, L. Apetoh, F. Ghiringhelli, L. Zitvogel, and G. Kroemer
Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from "Silent" to Immunogenic
Cancer Res.,
September 1, 2007;
67(17):
7941 - 7944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al.
Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Clin. Cancer Res.,
September 1, 2007;
13(17):
5133 - 5143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, W. Song, D. K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A. M. Krieg, and R. Levy
Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself
J. Immunol.,
August 15, 2007;
179(4):
2493 - 2500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini
Interleukin-12: Biological Properties and Clinical Application
Clin. Cancer Res.,
August 15, 2007;
13(16):
4677 - 4685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Harrop, N. Drury, W. Shingler, P. Chikoti, I. Redchenko, M. W. Carroll, S. M. Kingsman, S. Naylor, A. Melcher, J. Nicholls, et al.
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses
Clin. Cancer Res.,
August 1, 2007;
13(15):
4487 - 4494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. van der Burg, S. J. Piersma, A. de Jong, J. M. van der Hulst, K. M. C. Kwappenberg, M. van den Hende, M. J. P. Welters, J. J. Van Rood, G. J. Fleuren, C. J. M. Melief, et al.
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens
PNAS,
July 17, 2007;
104(29):
12087 - 12092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schlom, P. M. Arlen, and J. L. Gulley
Cancer Vaccines: Moving Beyond Current Paradigms
Clin. Cancer Res.,
July 1, 2007;
13(13):
3776 - 3782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tuve, B.-M. Chen, Y. Liu, T.-L. Cheng, P. Toure, P. S. Sow, Q. Feng, N. Kiviat, R. Strauss, S. Ni, et al.
Combination of Tumor Site-Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
Cancer Res.,
June 15, 2007;
67(12):
5929 - 5939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. v. Rhee
Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System
Clin. Cancer Res.,
March 1, 2007;
13(5):
1353 - 1355.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-Y. Hou, A. J. Muller, M. D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A. L. Mellor, G. C. Prendergast, and D. H. Munn
Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses
Cancer Res.,
January 15, 2007;
67(2):
792 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al.
Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration
Clin. Cancer Res.,
January 15, 2007;
13(2):
644 - 653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev
Reversal of Tumor-Mediated Immunosuppression
Clin. Cancer Res.,
January 15, 2007;
13(2):
727s - 732s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Brode, T. Raine, P. Zaccone, and A. Cooke
Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells
J. Immunol.,
November 15, 2006;
177(10):
6603 - 6612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-h. Lee, T. Kakinuma, J. Wang, H. Zhang, D. C. Palmer, N. P. Restifo, and S. T. Hwang
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Mol. Cancer Ther.,
October 1, 2006;
5(10):
2592 - 2599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Chaput, C. Flament, S. Viaud, J. Taieb, S. Roux, A. Spatz, F. Andre, J.-B. LePecq, M. Boussac, J. Garin, et al.
Dendritic cell derived-exosomes: biology and clinical implementations
J. Leukoc. Biol.,
September 1, 2006;
80(3):
471 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Knutson, Y. Dang, H. Lu, J. Lukas, B. Almand, E. Gad, E. Azeke, and M. L. Disis
IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice
J. Immunol.,
July 1, 2006;
177(1):
84 - 91.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Condomines, P. Quittet, Z.-Y. Lu, L. Nadal, P. Latry, E. Lopez, M. Baudard, G. Requirand, C. Duperray, J.-F. Schved, et al.
Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor.
J. Immunol.,
June 1, 2006;
176(11):
6631 - 6639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Taieb, N. Chaput, N. Schartz, S. Roux, S. Novault, C. Menard, F. Ghiringhelli, M. Terme, A. F. Carpentier, G. Darrasse-Jese, et al.
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.
J. Immunol.,
March 1, 2006;
176(5):
2722 - 2729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Arlen, J. L. Gulley, C. Parker, L. Skarupa, M. Pazdur, D. Panicali, P. Beetham, K. Y. Tsang, D. W. Grosenbach, J. Feldman, et al.
A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer
Clin. Cancer Res.,
February 15, 2006;
12(4):
1260 - 1269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Di Paolo, S. Tuve, S. Ni, K. E. Hellstrom, I. Hellstrom, and A. Lieber
Effect of Adenovirus-Mediated Heat Shock Protein Expression and Oncolysis in Combination with Low-Dose Cyclophosphamide Treatment on Antitumor Immune Responses
Cancer Res.,
January 15, 2006;
66(2):
960 - 969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Sato, S. H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A. A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, et al.
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
PNAS,
December 20, 2005;
102(51):
18538 - 18543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Emens and E. M. Jaffee
Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy
Cancer Res.,
September 15, 2005;
65(18):
8059 - 8064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Beyer, M. Kochanek, K. Darabi, A. Popov, M. Jensen, E. Endl, P. A. Knolle, R. K. Thomas, M. von Bergwelt-Baildon, S. Debey, et al.
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
Blood,
September 15, 2005;
106(6):
2018 - 2025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Loeffler, J. A. Kruger, and R. A. Reisfeld
Immunostimulatory Effects of Low-Dose Cyclophosphamide Are Controlled by Inducible Nitric Oxide Synthase
Cancer Res.,
June 15, 2005;
65(12):
5027 - 5030.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
